ALS patients continue experimental oral treatment in safety Follow-Up
NCT ID NCT05568615
Summary
This study followed patients who completed earlier trials of oral edaravone for ALS to monitor long-term safety. Fifteen participants in Japan took the medication in cycles until it became commercially available or until August 2023. The main goal was to track side effects and adverse reactions to understand the treatment's safety profile over extended use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fukushima Medical University Hospital
Fukushima, Fukushima, 960-1295, Japan
-
Kagawa University Hospital
Kita-gun, Kagawa-ken, 761-0793, Japan
-
Kitasato University Hospital
Sagamihara-shi, Kanagawa, 252-0375, Japan
-
National Epilepsy Center NHO Shizuoka Institute of Epilepsy and Neurological Disorders
Shizuoka, 420-8688, Japan
-
National Hospital Organization Chibahigashi National Hospital
Chiba, Chiba, 260-8712, Japan
-
National Hospital Organization Higashinagoya National Hospital
Nagoya, Aichi-ken, 465-8620, Japan
-
National Hospital Organization Kumamoto Saishun Medical Center
Kōshi, Kumamoto, 861-1196, Japan
-
National Hospital Organization Osaka Toneyama Medical Center
Toyonaka-shi, Osaka, 560-8552, Japan
-
Shiga University of Medical Science Hospital
Ōtsu, Shiga, 520-2192, Japan
-
Tokyo Metropolitan Neurological Hospital
Fuchu-shi, Tokyo, 183-0042, Japan
-
Yokohama City University Hospital
Yokohama, Kanagawa, 236-0004, Japan
Conditions
Explore the condition pages connected to this study.